Evidence map›Paper›PMID 29359183›Full record

ArticlemSphere

Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques.

Joshua A Eudailey, Maria L Dennis, Morgan E Parker, Bonnie L Phillips, Tori N Huffman, Camden P Bay, Michael G Hudgens, Roger W Wiseman, Justin J Pollara, Genevieve G Fouda and 6 more

Open access · goldAbstract read
In one paragraph

Article in mSphere. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Joshua A EudaileyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Maria L DennisDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Morgan E ParkerDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Bonnie L PhillipsDepartment of Microbiology and Immunology and Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Tori N HuffmanDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Camden P BayDepartment of Biostatistics, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Michael G HudgensDepartment of Biostatistics, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Roger W WisemanDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Justin J PollaraDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Genevieve G FoudaDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Guido FerrariDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
David J PickupDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Pamela A KozlowskiDepartment of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Centre, New Orleans, Louisiana, USA.
Koen K A Van RompayCalifornia National Primate Research Center, University of California at Davis, Davis, California, USA.
Kristina De ParisDepartment of Microbiology and Immunology and Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Sallie R PermarDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Duke Medical Center · USUniversity of North Carolina at Chapel Hill · USDuke University · USDuke University Hospital · USLouisiana State University Health Sciences Center New Orleans · USUniversity of California, Davis · USUniversity of Wisconsin–Madison · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Project 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responsesP01AI117915 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE PARIS, KRISTINA, PERMAR, SALLIE R. · 2015 to 2024
$21.2M
Basic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2M
Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigensK01OD024877 · OD · DUKE UNIVERSITY · PI POLLARA, JUSTIN JOSEPH · 2017 to 2019
$1.0M
6 · The paper itself

Abstract

Mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) contributes to an estimated 150,000 new infections annually. Maternal vaccination has proven safe and effective at mitigating the impact of other neonatal pathogens and is one avenue toward generating the potentially protective immune responses necessary to inhibit HIV-1 infection of infants through breastfeeding. In the present study, we tested the efficacy of a maternal vaccine regimen consisting of a modified vaccinia virus Ankara (MVA) 1086.C gp120 prime-combined intramuscular-intranasal gp120 boost administered during pregnancy and postpartum to confer passive protection on infant rhesus macaques against weekly oral exposure to subtype C simian-human immunodeficiency virus 1157ipd3N4 (SHIV1157ipd3N4) starting 6 weeks after birth. Despite eliciting a robust systemic envelope (Env)-specific IgG response, as well as durable milk IgA responses, the maternal vaccine did not have a discernible impact on infant oral SHIV acquisition. This study revealed considerable variation in vaccine-elicited IgG placental transfer and a swift decline of both Env-specific antibodies (Abs) and functional Ab responses in the infants prior to the first challenge, illustrating the importance of pregnancy immunization timing to elicit optimal systemic Ab levels at birth. Interestingly, the strongest correlation to the number of challenges required to infect the infants was the percentage of activated CD4

Indexed as

breast milkHIV-1maternal vaccinationoral challengeplacental transfertransmission

Identifiers

PMID29359183
PMCPMC5760748
OpenAlexW2783463171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.